News

StemBioSys raises $4.3M; sees itself as a “different company” ready to leverage new funding

StemBioSys Inc. CEO Bob Hutchens says the San Antonio biotech is on track to significantly expand its ...

Health Tech Panelists Stress Need for Collisions’ Among Local Industries

David Spencer (left) and Dr. George Peoples speak about collaboration between the local entrepreneur ...

Events

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
News
Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research
February 22, 2018

By David Holley, Xconomy

San Antonio—A small Texas biotech that develops women’s health products, including a generic birth control ring, has received a $960,000 grant from the Department of Defense to continue early stage work on experimental treatments for triple-negative breast cancer.

Evestra, which is located just outside of San Antonio, in Schertz, TX, plans to use the three-year grant to study the toxicology and pharmacology of its potential candidates of antiprogestins, according to CEO Ze’ev Shaked. Antiprogestins play a role regulating hormones, and may stop cancer cell growth, according to the National Cancer Institute. The company will also work with Ratna Vadlamudi, a professor and researcher at the University of Texas Health Science Center at San Antonio, on animal studies of the therapeutics. Ratna is also receiving $761,298 in grant funding from the DoD for the work.

The antiprogestins are being studied as cytotoxic anti-tumor agents, and may have a range of cancer applications in addition to breast cancer, Evestra chief scientific officer Klaus Nickisch said in a news release. Evestra’s compounds take aim at a type of protein known as leukemia inhibitory factor, which can play a role in tumor cell growth; it appears the Evestra treatments may inhibit that, which Shaked says would be a new class of anti-cancer compounds.

“This was a highly unusual finding since this class of compounds (antiprogestins) do not exhibit such strong cytotoxic activity,” Shaked wrote in an e-mail.

Evestra is developing a variety of women’s healthcare products, including treatments for endometriosis and fibroids, which both affect the uterus, and a generic version of the NuvaRing birth control product, which Evestra hopes to bring to market in 2019 with the U.S. division of Mumbai, India-based Glenmark Pharmaceuticals.

Earlier this year, Budapest, Hungary pharmaceutical firm Gedeon Richter acquired an undisclosed equity stake in Evestra.

Stay informed. Subscribe to BioMed SA news alerts.